Novel method to measure the intrinsic spatial resolution in PET detectors based on monolithic crystals

[EN] The main aim of this work is to provide a method to retrieve the intrinsic spatial resolution of a gamma-ray detector block based on monolithic crystals within an assembled scanner. This method consists on a discrimination of the data using a software collimation process. The results are compared with an alternative method of separating two detector blocks far enough to produce a "virtual" source collimation due to the geometric constraints on the allowed coincidence event angles. A theoretical model has been deduced to fit the measured light distribution profiles, allowing estimating the detector intrinsic spatial resolution. The detector intrinsic spatial resolution is expected to follow a Gaussian distribution and the positron-emitter source shape, given the small size of a Na-22 source with 0.25 mm in diameter, can be assumed to follow a Lorentzian profile. However, the collimation of the data modifies the source shape that is no longer a pure Lorentzian distribution. Therefore, the model is based on the convolution of a Gaussian shaped distribution (contribution of the detector) and a modified Lorentzian distribution (contribution of the collimated source profile) that takes into account the collimation effect. Three LYSO crystals geometries have been studied in the present work, namely a 10 mm thick trapezoidal monolithic block, and two rectangular monolithic blocks with thicknesses of 15 mm and 20 mm, respectively. All the blocks have size dimensions of 50 mm x 50 mm. The experimental results yielded an intrinsic detector spatial resolution of 0.64 +/- 0.02 mm, 0.82 +/- 0.02 and 1.07 +/- 0.03 mm, for the 10 mm, 15 mm and 20 mm thick blocks, respectively, when the source was placed at the center of the detector. The detector intrinsic spatial resolution was moreover evaluated across one of the axis of each crystal. These values worsen to an average value of 0.68 +/- 0.04 mm, 0.90 +/- 0.14 and 1.29 +/- 0.19 mm, respectively, when the whole crystal size is considered, as expected. These tests show an accurate method to determine the intrinsic spatial resolution of monolithic-based detector blocks, once assembled in the PET system.This project has received funding from the European Research Council, Spain (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 695536). It has also been supported by the EU, Spain Grant 603002 under the FP7 program, and by the Spanish Ministerio de Economia, Industria y Competitividad under Grant TEC2016-79884-C2-1-R and through PROSPET (DTS15/00152) funded by the Ministerio de Economia y Competitividad, Spain.González, A.; Sanchez, F.; Bruyndonckx, P.; Cañizares-Ledo, G.; Benlloch Baviera, JM.; González Martínez, AJ. (2019). Novel method to measure the intrinsic spatial resolution in PET detectors based on monolithic crystals. Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment. 920:58-67. https://doi.org/10.1016/j.nima.2018.12.056S586792

Using microbiological data to improve the use of antibiotics for respiratory tract infections: a protocol for an individual patient data meta-analysis

Background Resistance to antibiotics is rising and threatens future antibiotic effectiveness. ‘Antibiotic targeting’ ensures patients who may benefit from antibiotics receive them, while being safely withheld from those who may not. Point-of-care tests may assist with antibiotic targeting by allowing primary care clinicians to establish if symptomatic patients have a viral, bacterial, combined, or no infection. However, because organisms can be harmlessly carried, it is important to know if the presence of the virus/bacteria is related to the illness for which the patient is being assessed. One way to do this is to look for associations with more severe/prolonged symptoms and test results. Previous research to answer this question for acute respiratory tract infections has given conflicting results with studies has not having enough participants to provide statistical confidence. Aim To undertake a synthesis of IPD from both randomised controlled trials (RCTs) and observational cohort studies of respiratory tract infections (RTI) in order to investigate the prognostic value of microbiological data in addition to, or instead of, clinical symptoms and signs. Methods A systematic search of Cochrane Central Register of Controlled Trials, Ovid Medline and Ovid Embase will be carried out for studies of acute respiratory infection in primary care settings. The outcomes of interest are duration of disease, severity of disease, repeated consultation with new/worsening illness and complications requiring hospitalisation. Authors of eligible studies will be contacted to provide anonymised individual participant data. The data will be harmonised and aggregated. Multilevel regression analysis will be conducted to determine key outcome measures for different potential pathogens and whether these offer any additional information on prognosis beyond clinical symptoms and signs. Trial registration PROSPERO Registration number: CRD42023376769

Number of addictive substances used related to increased risk of unnatural death: A combined medico-legal and case-record study

<p>Abstract</p> <p>Background</p> <p>Substance use disorders have repeatedly been found to lead to premature death, i.e. drug-related death by disease, fatal intoxications, or trauma (accidents, suicide, undetermined suicide, and homicide). The present study examined the relationship between multi-drug substance use and natural and unnatural death.</p> <p>Methods</p> <p>All consecutive, autopsied patients who had been in contact with the Addiction Centre in Malmö University Hospital from 1993 to 1997 inclusive were investigated. Drug abuse was investigated blindly in the case records and related to the cause of death in 387 subjects.</p> <p>Results</p> <p>Every substance apart from alcohol used previously in life added to the risk of unnatural death in a linear way. There were independent increased risks of fatal heroin overdoses or undetermined suicide. Death by suicide and violent death were unrelated to additional abuse.</p> <p>Conclusion</p> <p>The number of drugs used was related to an increased risk of unnatural death by undetermined suicide (mainly fatal intoxications) and heroin overdose.</p

Using microbiological data to improve the use of antibiotics for respiratory tract infections: A protocol for an individual patient data meta-analysis

Background Resistance to antibiotics is rising and threatens future antibiotic effectiveness. ‘Antibiotic targeting’ ensures patients who may benefit from antibiotics receive them, while being safely withheld from those who may not. Point-of-care tests may assist with antibiotic targeting by allowing primary care clinicians to establish if symptomatic patients have a viral, bacterial, combined, or no infection. However, because organisms can be harmlessly carried, it is important to know if the presence of the virus/bacteria is related to the illness for which the patient is being assessed. One way to do this is to look for associations with more severe/ prolonged symptoms and test results. Previous research to answer this question for acute respiratory tract infections has given conflicting results with studies has not having enough participants to provide statistical confidence. Aim To undertake a synthesis of IPD from both randomised controlled trials (RCTs) and observational cohort studies of respiratory tract infections (RTI) in order to investigate the prognostic value of microbiological data in addition to, or instead of, clinical symptoms and signs. Methods A systematic search of Cochrane Central Register of Controlled Trials, Ovid Medline and Ovid Embase will be carried out for studies of acute respiratory infection in primary care settings. The outcomes of interest are duration of disease, severity of disease, repeated consultation with new/worsening illness and complications requiring hospitalisation. Authors of eligible studies will be contacted to provide anonymised individual participant data. The data will be harmonised and aggregated. Multilevel regression analysis will be conducted to determine key outcome measures for different potential pathogens and whether these offer any additional information on prognosis beyond clinical symptoms and signs

Using microbiological data to improve the use of antibiotics for respiratory tract infections: A protocol for an individual patient data meta-analysis

Background: Resistance to antibiotics is rising and threatens future antibiotic effectiveness. ‘Antibiotic targeting’ ensures patients who may benefit from antibiotics receive them, while being safely withheld from those who may not. Point-of-care tests may assist with antibiotic targeting by allowing primary care clinicians to establish if symptomatic patients have a viral, bacterial, combined, or no infection. However, because organisms can be harmlessly carried, it is important to know if the presence of the virus/bacteria is related to the illness for which the patient is being assessed. One way to do this is to look for associations with more severe/prolonged symptoms and test results. Previous research to answer this question for acute respiratory tract infections has given conflicting results with studies has not having enough participants to provide statistical confidence. Aim: To undertake a synthesis of IPD from both randomised controlled trials (RCTs) and observational cohort studies of respiratory tract infections (RTI) in order to investigate the prognostic value of microbiological data in addition to, or instead of, clinical symptoms and signs. Methods: A systematic search of Cochrane Central Register of Controlled Trials, Ovid Medline and Ovid Embase will be carried out for studies of acute respiratory infection in primary care settings. The outcomes of interest are duration of disease, severity of disease, repeated consultation with new/worsening illness and complications requiring hospitalisation. Authors of eligible studies will be contacted to provide anonymised individual participant data. The data will be harmonised and aggregated. Multilevel regression analysis will be conducted to determine key outcome measures for different potential pathogens and whether these offer any additional information on prognosis beyond clinical symptoms and signs. Trial registration: PROSPERO Registration number: CRD42023376769

Using microbiological data to improve the use of antibiotics for respiratory tract infections: A protocol for an individual patient data meta-analysis

Background Resistance to antibiotics is rising and threatens future antibiotic effectiveness. ‘Antibiotic targeting’ ensures patients who may benefit from antibiotics receive them, while being safely withheld from those who may not. Point-of-care tests may assist with antibiotic targeting by allowing primary care clinicians to establish if symptomatic patients have a viral, bacterial, combined, or no infection. However, because organisms can be harmlessly carried, it is important to know if the presence of the virus/bacteria is related to the illness for which the patient is being assessed. One way to do this is to look for associations with more severe/prolonged symptoms and test results. Previous research to answer this question for acute respiratory tract infections has given conflicting results with studies has not having enough participants to provide statistical confidence. Aim To undertake a synthesis of IPD from both randomised controlled trials (RCTs) and observational cohort studies of respiratory tract infections (RTI) in order to investigate the prognostic value of microbiological data in addition to, or instead of, clinical symptoms and signs. Methods A systematic search of Cochrane Central Register of Controlled Trials, Ovid Medline and Ovid Embase will be carried out for studies of acute respiratory infection in primary care settings. The outcomes of interest are duration of disease, severity of disease, repeated consultation with new/worsening illness and complications requiring hospitalisation. Authors of eligible studies will be contacted to provide anonymised individual participant data. The data will be harmonised and aggregated. Multilevel regression analysis will be conducted to determine key outcome measures for different potential pathogens and whether these offer any additional information on prognosis beyond clinical symptoms and signs. Trial registration PROSPERO Registration number: CRD42023376769

Performance study of a 3D small animal PET scanner based on BaF2 crystals and a photo sensitive wire chamber

A 3D small animal PET scanner, designed and built at the University of Brussel, has been operational since the beginning of 1996. The scanner has a transaxial field of view (FOV) of 110 mm and an axial FOV of 52 mm. The absolute sensitivity is around 35,000 coincidences s-1 MBq-1 for a point source at the center of the scanner and the time resolution is 29 ns FWHM. To measure the achievable spatial resolution, a thin 22Na source was scanned at various distances from the scanner axis. The resolution in a reconstructed image for a source close to the center is 3.0 mm FWHM. This figure can be improved at the expense of the sensitivity by lowering the voltage on the anodes in the wire chamber. Finally, to assess the overall image quality, scans were made of a cylindrical phantom with holes of varying diameter.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Study of a high resolution 3D PET scanner

Some results of a study of the properties of a low pressure multistep avalanche chamber with BaF2 scintillators and with TMAE as the photosensitive gas for a 3D PET scanner are presented. Absolute gas amplification was carefully measured by two independent methods, giving rise to a maximum attainable total gain of the order of 107. A typical electron transmission efficiency of 20-30% was obtained. The time resolution of the detector can be optimized to be ∼ 6 ns FWHM. © 1994.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

BaF2 scintillators with wire chamber readout for positron emission tomography

This work is part of the design study for a medical positron emission tomography (PET) system based on the use of BaF2 scintillator and photosensitive wire chambers with TMAE. The number of photoelectrons per MEV (phe/MeV) is measured in the wire chamber and on a photomultiplier for crystals from five different suppliers. For the best crystals 26.7±2.0 phe/MeV in TMAE are observed, corresponding to an average quantum efficiency of TMAE for the fast component of BaF2 of (7.6±0.7)%. The performance of a PET scanner based on this principle was evaluated with a detailed Monte Carlo simulation. It is shown that the reduced energy resolution with wire chambers has only a marginal effect on the scatter rejection in the scanner. Finally LaF3:Nd3+ as an alternative to BaF2 was tested and found to give a disappointing photoelectron yield. © 1991.SCOPUS: ar.jinfo:eu-repo/semantics/publishe